Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On September 30, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced positive topline results from the single ascending dose (SAD) Part 1 portion of the ongoing Phase 1 clinical trial of DA-1726 for the treatment of obesity.</li><li>The results showed favorable safety, tolerability, and dose-linear pharmacokinetics (PK).</li><li>Based on the strong safety profile of DA-1726, one or more additional cohorts are being added to explore the maximum tolerated dose.</li></ul>

On September 30, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced positive topline results from the single ascending dose (SAD) Part 1 portion of the ongoing Phase 1 clinical trial of DA-1726 for the treatment of obesity.The results showed favorable safety, tolerability, and dose-linear pharmacokinetics (PK).Based on the strong safety profile of DA-1726, one or more additional cohorts are being added to explore the maximum tolerated dose.

NRBO:  Positive SAD Part 1 Data  MAD Part 2 Results Expected in 1Q25 

MetaVia

NRBO: Positive SAD Part 1 Data MAD Part 2 Results Expected in 1Q25